Current Report Filing (8-k)
03 December 2020 - 2:27AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE
COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of
1934
Date
of Report (Date of earliest event reported):
December 2,
2020
AYTU
BIOSCIENCE, INC.
(Exact
name of registrant as specified in its charter)
Delaware
|
|
001-38247
|
|
47-0883144
|
(State
or other jurisdiction of incorporation)
|
|
(Commission
File Number)
|
|
(IRS
Employer Identification No.)
|
373 Inverness Parkway, Suite 206
Englewood, CO 80112
(Address
of principal executive offices, including Zip Code)
Registrant’s
telephone number, including area code: (720) 437-580
N/A
(Former name or former address, if changed since last
report)
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
☐
Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
☐
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
☐
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b)
of the Act:
Title
of each class
|
Trading
Symbol(s)
|
Name
of each exchange on which registered
|
Common
Stock, par value $0.0001 per share
|
AYTU
|
The
NASDAQ Stock Market LLC
|
Indicate by check
mark whether the registrant is an emerging growth company as
defined in Rule 405 of the Securities Act of 1933 (§230.405 of
this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934
(§240.12b-2 of this chapter).
Emerging
growth company ☐
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act. ☐
Item
8.01 - Other Events
The
Company recently established a purchasing relationship with a U.S.
supplier of Emergency Use Authorization (EUA) authorized antigen
tests. Antigen tests rapidly detect the presence of the SARS-CoV-2
virus antigen via a nasopharyngeal swab and are used without
laboratory equipment. Demand for rapid antigen tests has increased
in recent months across the U.S. While the Company maintains a
distribution relationship to distribute the Pinnacle RAD Rapid
Antigen Detection test upon receipt of an EUA, that test remains in
the EUA process with the U.S. Food & Drug Administration.
Accordingly, the Company opportunistically purchased EUA rapid
antigen tests to distribute to its customers. An initial shipment
of EUA antigen tests has been received by the Company, and purchase
orders have been fulfilled. The Company expects to sell the
recently purchased EUA rapid antigen tests while awaiting EUA for
the Pinnacle test. Sales from the newly acquired EUA tests are
expected to contribute net revenue for the Company.
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
AYTU BIOSCIENCE,
INC.
|
|
|
|
|
|
Date: December
2, 2020
|
By:
|
/s/ Joshua R.
Disbrow
|
|
|
|
Joshua
R. Disbrow
|
|
|
|
Chief Executive
Officer
|
|
AYTU BioPharma (NASDAQ:AYTU)
Historical Stock Chart
From Apr 2024 to May 2024
AYTU BioPharma (NASDAQ:AYTU)
Historical Stock Chart
From May 2023 to May 2024